INTRODUCTION AND OBJECTIVES:
Debilitating pain in men with castration-resistant prostate cancer (CRPC) is one of the most common, yet understudied morbidities. There is evidence that baseline pain is an important predictor of survival outcome in men with CRPC. Understanding the dynamic nature of pain, we seek to develop a prognostic model of overall survival (OS) based on the longitudinal pain score trajectories in men with CRPC.
METHODS: 729 patients with metastatic CRPC from the control arms of three phase III, randomized, double-blind, placebo-controlled clinical trials (NCT00519285, NCT00988208, and NCT00638690) were accessed from the Prostate Data Sphere and were analyzed. Joint latent class modeling (JLCM) method was applied to stratify our study cohort into different subpopulations with three different pain score trajectories. Patient reported brief pain inventory (BPI) or the present pain intensity index (PPI) instruments were obtained to characterize longitudinal pain scores. The OS was measured as the time-to-event outcome from randomization to death or censoring.
RESULTS: 536 (73.5%) patients were found to have a stable pattern of pain scores. 111 (15.2%) and 82 (11.3%) patients had rapidly increasing and decreasing trends, respectively. Patients with stable pain levels had the most favorable OS while rapidly increasing pain was associated with the worst OS (HR: 11.36, p-value<0.01 when compared to those with stable pain).
CONCLUSIONS: Patients having both increasing and decreasing patterns of pain had higher risk of death when compared to those with stable pain levels. Longitudinal pain scores can be used as a prognostic factor for overall survival in patients suffering from metastatic CRPC.
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MP57-06 MANAGEMENT OF ENZALUTAMIDE-RELATED ADVERSE EVENTS FOR CRPC PATIENTS BY USING PATIENT REPORTED OUTCOMES LEADS BETTER PROGNOSIS.
Taro Iguchi*, Sayaka Yasuda, Minoru Kato, Takeshi Yamasaki, Yasuomi Shimizu, Yuji Takeyama, Satoshi Tamada, Tatsuya Nakatani, Osaka, Japan INTRODUCTION AND OBJECTIVES: The clinical benefit of enzalutamide for castration-resistant prostate cancer (CRPC) is its high efficacy and favorable safety profile. Subjective symptoms such as fatigue and appetite loss, which are common adverse effects (AEs) for enzalutamide, tend to be underestimated in clinical trials and may lead discontinuation of enzalutamide. Recently, attention has been directed at patient reported outcomes (PROs) as selfadministrated assessment in the health-related quality of life (HRQoL) evaluation of cancer patients. The identification of PROs by questionnaires for subjective AEs are important in the clinical practice for their impact on HRQoL and may be different from doctor reported outcomes (DROs).
METHODS: Fifty-eight CRPC patients (39 pre and 19 post docetaxel) treated with enzalutamide were assessed by PROs for subjective AEs at the time of the medical visit.
RESULTS: Although 44 and 40 of 58 patients reported fatigue and appetite loss by PRO, only 32 and 24 patients had G1 or over fatigue and appetite loss by doctor reported outcomes (DROs) ( Table. 1). Eighteen patients needed the dose reduction or interruption by fatigue or appetite loss and 14 of 18 patients, their subjective symptoms were improved quickly and they can continue to take without AEs (Fig. 1) . Surprisingly, the patients who needed the dose reduction of enzalutamide had longer time to treatment failure (Fig.2) .
CONCLUSIONS: The DROs assessment of subjective AEs of enzalutamide differed from the PRO assessment. The prompt dose reduction of enzalutamide in response to the PRO assessment improved the symptoms and prevented dropping out due to AEs. PRO assessment is a useful tool to rapidly identify AEs which can lead to prompt dose modification, decreased patient drop out and improved outcomes to Enzalutamide treatment. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e765
